A recombinant humanized monoclonal antibody completely protects mice against lethal challenge with Venezuelan equine encephalitis virus

Vaccine

Volumn 28, Issue 34, 2010, Pages 5558-5564

  Hu, Wei Gang ^a   Phelps, Amanda L ^b   Jager, Scott ^a   Chau, Damon ^a   Hu, Charles C ^c   O'Brien, Lyn M ^b   Perkins, Stuart D ^b   Gates, Amanda J ^b   Phillpotts, Robert J ^b   Nagata, Les P ^a  

^a DEFENCE RESEARCH AND DEVELOPMENT CANADA   (Canada)

^b DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

^c UNIVERSITY OF WATERLOO   (Canada)

Author keywords

Prophylactic and therapeutic effects; Recombinant humanized antibody; Venezuelan equine encephalitis virus

Indexed keywords

ADENOVIRUS VECTOR; ANTIBODY; HU1A4A1IGG1 2A VACCINE; HUMAN MONOCLONAL ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; OLIGOPEPTIDE; RECOMBINANT ANTIBODY; RECOMBINANT HUMANIZED MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY; VIRUS PROTEIN; VIRUS PROTEIN 2A;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DIMERIZATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; FOOT AND MOUTH DISEASE VIRUS; GENE EXPRESSION; IMMUNITY; IMMUNIZATION; INFECTION PREVENTION; LD 50; MAMMAL CELL; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN PURIFICATION; VENEZUELAN EQUINE ENCEPHALITIS; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; VIRULENCE; ANIMAL; ANTIBODY SPECIFICITY; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL LINE; ENCEPHALOMYELITIS, VENEZUELAN EQUINE; HALF LIFE TIME; HUMAN; IMMUNOLOGY; SERODIAGNOSIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; CELL LINE; ENCEPHALITIS VIRUS, VENEZUELAN EQUINE; ENCEPHALOMYELITIS, VENEZUELAN EQUINE; HALF-LIFE; HUMANS; IMMUNIZATION, PASSIVE; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; VIRAL PROTEINS;

EID: 77955056640     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.06.038     Document Type: Article

References (35)

1. Weaver S.C., Ferro C., Barrera R., Boshell J., Navarro J.C. Venezuelan equine encephalitis. Annu Rev Entomol 2004, 49:141-174.
2. Griffin D.E. Alphaviruses. Fields virology 2001, 937-941. Lippincott-Raven, Philadelphia, PA. 4th ed. D.M. Knipe, P.M. Howley (Eds.).
3. Rivas F., Diaz L.A., Cardenas V.M., Daza E., Bruzon L., Alcala A., et al. Epidemic Venezuelan equine encephalitis in La Guajira, Colombia, 1995. J Infect Dis 1997, 175(April (4)):828-832.
4. Hawley R.J., Eitzen E.M. Biological weapons-a primer for microbiologists. Annu Rev Microbiol 2001, 55:235-253.
5. Sawyer L.A. Antibodies for the prevention and treatment of viral diseases. Antiviral Res 2000, 47(August (2)):57-77.
6. France J.K., Wyrick B.C., Trent D.W. Biochemical and antigenic comparison of the envelope glycoproteins of Venezuelan equine encephalomyelitis virus strains. J Gen Virol 1979, 44(September (3)):725-740.
7. Roehrig J.T., Day J.W., Kinney R.M. Antigenic analysis of the surface glycoproteins of a Venezuelan equine encephalomyelitis virus (TC-83) using monoclonal antibodies. Virology 1982, 118(April (2)):269-278.
8. Roehrig J.T., Mathews J.H. The neutralization site on the E2 glycoprotein of Venezuelan equine encephalomyelitis (TC-83) virus is composed of multiple conformationally stable epitopes. Virology 1985, 142(April (2)):347-356.
9. Phillpotts R.J., Jones L.D., Howard S.C. Monoclonal antibody protects mice against infection and disease when given either before or up to 24h after airborne challenge with virulent Venezuelan equine encephalitis virus. Vaccine 2002, 20(February (11-12)):1497-1504.
10. Phillpotts R.J. Venezuelan equine encephalitis virus complex-specific monoclonal antibody provides broad protection, in murine models, against airborne challenge with viruses from serogroups I, II and III. Virus Res 2006, 120(September (1-2)):107-112.
11. Hu W.G., Chau D., Wu J., Jager S., Nagata L.P. Humanization and mammalian expression of a murine monoclonal antibody against Venezuelan equine encephalitis virus. Vaccine 2007, 25(April (16)):3210-3214.
12. Friguet B., Chaffotte A.F., Djavadi-Ohaniance L., Goldberg M.E. Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay. J Immunol Methods 1985, 77(March (2)):305-319.
13. Wright A.J., Phillpotts R.J. Humane endpoints are an objective measure of morbidity in Venezuelan encephalomyelitis virus infection of mice. Arch Virol 1998, 143(6):1155-1162.
14. Davies J.S., Holter J.L., Knight D., Beaucourt S.M., Murphy D., Carter D.A., et al. Manipulating sorting signals to generate co-expression of somatostatin and eGFP in the regulated secretory pathway from a monocistronic construct. J Mol Endocrinol 2004, 33(October (2)):523-532.
15. Mizuguchi H., Xu Z., Ishii-Watabe A., Uchida E., Hayakawa T. IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector. Mol Ther 2000, 1(April (4)):376-382.
16. Jerecic J., Single F., Kruth U., Krestel H., Kolhekar R., Storck T., et al. Studies on conditional gene expression in the brain. Ann NY Acad Sci 1999, 868(April):27-37.
17. Fang J., Qian J.J., Yi S., Harding T.C., Tu G.H., VanRoey M., et al. Stable antibody expression at therapeutic levels using the 2A peptide. Nat Biotechnol 2005, 23(May (5)):584-590.
18. Reed C.D., Rast H., Hu W.G., Mah D., Nagata L., Masri S.A. Expression of furin-linked Fab fragments against anthrax toxin in a single mammalian expression vector. Protein Exp Purif 2007, 54(August (2)):261-266.
19. Donnelly M.L., Luke G., Mehrotra A., Li X., Hughes L.E., Gani D., et al. Analysis of the aphthovirus 2A/2B polyprotein 'cleavage' mechanism indicates not a proteolytic reaction, but a novel translational effect: a putative ribosomal 'skip'. J Gen Virol 2001, 82(May (Pt 5)):1013-1025.
20. Szymczak A.L., Workman C.J., Wang Y., Vignali K.M., Dilioglou S., Vanin E.F., et al. Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. Nat Biotechnol 2004, 22(May (5)):589-594.
21. Charles P.C., Walters E., Margolis F., Johnston R.E. Mechanism of neuroinvasion of Venezuelan equine encephalitis virus in the mouse. Virology 1995, 208(April (2)):662-671.
22. Jackson A.C., SenGupta S.K., Smith J.F. Pathogenesis of Venezuelan equine encephalitis virus infection in mice and hamsters. Vet Pathol 1991, 28(September (5)):410-418.
23. Vogel P., Abplanalp D., Kell W., Ibrahim M.S., Downs M.B., Pratt W.D., et al. Venezuelan equine encephalitis in BALB/c mice: kinetic analysis of central nervous system infection following aerosol or subcutaneous inoculation. Arch Pathol Lab Med 1996, 120(February (2)):164-172.
24. Schoneboom B.A., Catlin K.M., Marty A.M., Grieder F.B. Inflammation is a component of neurodegeneration in response to Venezuelan equine encephalitis virus infection in mice. J Neuroimmunol 2000, 109(September (2)):132-146.
25. Johnston R.E., Peters C.J. Alphaviruses. Fields virology 1995, 843-898. Lippincott-Raven, New York. 3rd ed. B.N. Fields, D.M. Knipe, P.M. Howley (Eds.).
26. Phillpotts R.J., Wright A.J. TC-83 vaccine protects against airborne or subcutaneous challenge with heterologous mouse-virulent strains of Venezuelan equine encephalitis virus. Vaccine 1999, 17(February (7-8)):982-988.
27. Davson H. Review lecture. The blood-brain barrier. J Physiol 1976, 255(February (1)):1-28.
28. Hu W.G., Nagata L.P. Antibody gene-based prophylaxis and therapy for biodefence. Hum Vacc 2008, 4(January-February (1)):74-78.
29. Hunt A.R., Frederickson S., Hinkel C., Bowdish K.S., Roehrig J.T. A humanized murine monoclonal antibody protects mice either before or after challenge with virulent Venezuelan equine encephalomyelitis virus. J Gen Virol 2006, 87(September (Pt 9)):2467-2476.
30. Johnson B.J., Brubaker J.R., Roehrig J.T., Trent D.W. Variants of Venezuelan equine encephalitis virus that resist neutralization define a domain of the E2 glycoprotein. Virology 1990, 177(August (2)):676-683.
31. Bakker A.B., Marissen W.E., Kramer R.A., Rice A.B., Weldon W.C., Niezgoda M., et al. Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants. J Virol 2005, 79(July (14)):9062-9068.
32. Goudsmit J., Marissen W.E., Weldon W.C., Niezgoda M., Hanlon C.A., Rice A.B., et al. Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin. J Infect Dis 2006, 193(March (6)):796-801.
33. Sanna P.P., Ramiro-Ibanez F., De Logu A. Synergistic interactions of antibodies in rate of virus neutralization. Virology 2000, 270(May (2)):386-396.
34. Ciurea A., Hunziker L., Zinkernagel R.M., Hengartner H. Viral escape from the neutralizing antibody response: the lymphocytic choriomeningitis virus model. Immunogenetics 2001, 53(April (3)):185-189.
35. Ciurea A., Klenerman P., Hunziker L., Horvath E., Senn B.M., Ochsenbein A.F., et al. Viral persistence in vivo through selection of neutralizing antibody-escape variants. Proc Natl Acad Sci USA 2000, 97(March (6)):2749-2754.